Tyrosine kinase inhibitor dasatinib, which is used to treat chronic myeloid leukemia (CML), inhibits HIV‐1 infection in CD4+ T cells by preserving SAMHD1 antiviral activity. Here, SAMHD1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.